Northwestern Mutual Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $303K | Buy |
916
+335
| +58% | +$114K | ﹤0.01% | 1733 |
|
|
2025
Q4 | $231K | Buy |
581
+14
| +2% | +$6.2K | ﹤0.01% | 1802 |
|
|
2025
Q3 | $259K | Buy |
567
+71
| +14% | +$28.9K | ﹤0.01% | 1693 |
|
|
2025
Q2 | $162K | Sell |
496
-29
| -6% | -$8.03K | ﹤0.01% | 1827 |
|
|
2025
Q1 | $142K | Buy |
525
+49
| +10% | +$12.6K | ﹤0.01% | 1801 |
|
|
2024
Q4 | $112K | Sell |
476
-47
| -9% | -$12.4K | ﹤0.01% | 1881 |
|
|
2024
Q3 | $144K | Sell |
523
-73
| -12% | -$19K | ﹤0.01% | 1750 |
|
|
2024
Q2 | $145K | Buy |
596
+250
| +72% | +$39.5K | ﹤0.01% | 1678 |
|
|
2024
Q1 | $51.7K | Sell |
346
-180
| -34% | -$30K | ﹤0.01% | 2059 |
|
|
2023
Q4 | $101K | Buy |
526
+46
| +10% | +$7.83K | ﹤0.01% | 1781 |
|
|
2023
Q3 | $85K | Buy |
480
+45
| +10% | +$8.59K | ﹤0.01% | 1771 |
|
|
2023
Q2 | $82.6K | Sell |
435
-96
| -18% | -$19K | ﹤0.01% | 1800 |
|
|
2023
Q1 | $106K | Buy |
531
+158
| +42% | +$33.2K | ﹤0.01% | 1664 |
|
|
2022
Q4 | $88.6K | Buy |
373
+139
| +59% | +$29.6K | ﹤0.01% | 1706 |
|
|
2022
Q3 | $47K | Sell |
234
-166
| -42% | -$31.7K | ﹤0.01% | 1922 |
|
|
2022
Q2 | $59K | Sell |
400
-206
| -34% | -$29.2K | ﹤0.01% | 1853 |
|
|
2022
Q1 | $98K | Buy |
606
+5
| +0.8% | +$762 | ﹤0.01% | 1712 |
|
|
2021
Q4 | $102K | Hold |
601
| – | – | ﹤0.01% | 1700 |
|
|
2021
Q3 | $114K | Hold |
601
| – | – | ﹤0.01% | 1569 |
|
|
2021
Q2 | $102K | Buy |
601
+231
| +62% | +$33.8K | ﹤0.01% | 1577 |
|
|
2021
Q1 | $52K | Buy |
370
+41
| +12% | +$6.17K | ﹤0.01% | 1725 |
|
|
2020
Q4 | $43K | Buy |
329
+21
| +7% | +$2.8K | ﹤0.01% | 1694 |
|
|
2020
Q3 | $45K | Buy |
308
+33
| +12% | +$4.69K | ﹤0.01% | 1541 |
|
|
2020
Q2 | $41K | Hold |
275
| – | – | ﹤0.01% | 1509 |
|
|
2020
Q1 | $30K | Sell |
275
-151
| -35% | -$17.4K | ﹤0.01% | 1566 |
|
|
2019
Q4 | $49K | Sell |
426
-514
| -55% | -$51.2K | ﹤0.01% | 1468 |
|
|
2019
Q3 | $76K | Buy |
940
+158
| +20% | +$12.5K | ﹤0.01% | 1255 |
|
|
2019
Q2 | $57K | Buy |
782
+81
| +12% | +$6.21K | ﹤0.01% | 1332 |
|
|
2019
Q1 | $66K | Buy |
701
+511
| +269% | +$42.7K | ﹤0.01% | 1235 |
|
|
2018
Q4 | $14K | Buy |
190
+100
| +111% | +$7.69K | ﹤0.01% | 1717 |
|
|
2018
Q3 | $8K | Buy |
+90
| New | +$9.05K | ﹤0.01% | 1971 |
|
|
2016
Q3 | – | Sell |
-7
| Closed | – | – | 232 |
|
|
2016
Q2 | $0 | Buy |
+7
| New | +$441 | ﹤0.01% | 2046 |
|
Other funds holding ALNY
VPM
VCM
Northwestern Mutual Wealth Management's ALNY Position: Q1 2026 in Review
Northwestern Mutual Wealth Management increased its Alnylam Pharmaceuticals (ALNY) stake by 58% in Q1 2026, buying an estimated $114K and bringing the position to 916 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #1733.
Northwestern Mutual Wealth Management first reported a position in ALNY in Q2 2016 and has held it in 32 quarters since. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Northwestern Mutual Wealth Management held 916 shares of Alnylam Pharmaceuticals worth $303K as of Q1 2026.
- Northwestern Mutual Wealth Management bought 335 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $114K.
- Alnylam Pharmaceuticals made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q1 2026, its #1733 holding.
- Northwestern Mutual Wealth Management first reported a position in Alnylam Pharmaceuticals in Q2 2016 and has held it in 32 quarters since.
- 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.